Odyssey Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Odyssey Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jul 31, 2020 | $0 | Nov 16, 2020 |
| FY2021 | Jul 31, 2019 | $0 | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | $0 | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | $0 | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | $37.5K | Nov 14, 2017 |
| FY2016 | Jul 31, 2015 | $257.2K | Nov 2, 2016 |
| FY2015 | Jul 31, 2014 | $0 | Dec 1, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jul 31, 2020 | $0 | Nov 16, 2020 |
| FY2021 | Jul 31, 2019 | $0 | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | $0 | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | $0 | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | $17.2K | Nov 14, 2017 |
| FY2016 | Jul 31, 2015 | $28.7K | Nov 2, 2016 |
| FY2015 | Jul 31, 2014 | $0 | Dec 1, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($1.74M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($842.3K) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($5.92M) | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | ($8.44M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($16.88M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($4.35M) | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | ($23.43M) | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | ($483.1K) | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | ($197.8K) | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | ($86.1K) | Nov 14, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($1.02M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($2.14M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($5.31M) | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | ($8.11M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($15.86M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($3.85M) | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | ($23.58M) | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | ($420.4K) | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | ($167.6K) | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | ($73.6K) | Nov 14, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $0 | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $55.2K | Oct 29, 2025 |
| FY2021 | Jul 31, 2021 | $1.63M | Oct 29, 2021 |
| FY2021 | Jul 31, 2020 | $20.2K | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | $23.01M | Nov 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($347.4K) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($1.22M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($1.47M) | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | ($1.47M) | Oct 30, 2023 |
| FY2023 | Jul 31, 2021 | ($3.18M) | Oct 30, 2023 |
| FY2021 | Jul 31, 2020 | ($649.1K) | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | ($104.8K) | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | ($146.1K) | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | ($116.6K) | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | ($60.9K) | Nov 14, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jul 31, 2017 | $0 | Nov 14, 2017 |
| FY2017 | Jul 31, 2016 | $3.3K | Nov 14, 2017 |
| FY2016 | Jul 31, 2015 | $0 | Nov 2, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $49.7K | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $586.1K | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $455.8K | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | $569.7K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $610.5K | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $105.6K | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | $536.4K | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | $27.5K | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | $159.3K | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | $68.4K | Nov 14, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jul 31, 2021 | $3.38M | Oct 29, 2021 |
| FY2021 | Jul 31, 2020 | $757.1K | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | $1.13M | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | $846.8K | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | $579.1K | Dec 12, 2018 |
| FY2015 | Jul 31, 2015 | $163.7K | Dec 1, 2015 |
| FY2015 | Jul 31, 2014 | $253.6K | Dec 1, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($6.95M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($5.33M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2023 | ($6.16M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2022 | ($4.64M) | Nov 13, 2024 |
| FY2023 | Jul 31, 2021 | ($2.77M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2020 | ($651.5K) | Oct 31, 2022 |
| FY2021 | Jul 31, 2019 | ($593.8K) | Oct 29, 2021 |
| FY2021 | Jul 31, 2018 | ($819.4K) | Nov 16, 2020 |
| FY2019 | Jul 31, 2017 | ($419.9K) | Nov 13, 2020 |
| FY2018 | Jul 31, 2016 | ($244.4K) | Dec 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($62.75M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($61.00M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($60.10M) | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | ($54.18M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($45.73M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($28.85M) | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | ($24.50M) | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | ($1.07M) | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | ($589.8K) | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | ($391.9K) | Nov 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jul 31, 2023 | $36.9K | Oct 30, 2023 |
| FY2022 | Jul 31, 2022 | $72.5K | Oct 31, 2022 |
| FY2021 | Jul 31, 2021 | $556.6K | Oct 29, 2021 |
| FY2021 | Jul 31, 2020 | $63.0K | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | $167.1K | Oct 29, 2021 |
| FY2021 | Jul 31, 2018 | $390 | Nov 16, 2020 |
| FY2019 | Jul 31, 2017 | $13.4K | Nov 13, 2020 |
| FY2018 | Jul 31, 2016 | $2.2K | Dec 12, 2018 |
| FY2017 | Apr 30, 2016 | $14.9K | Nov 14, 2017 |
| FY2017 | Jul 31, 2015 | $5.4K | Nov 14, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jul 31, 2021 | $0 | Oct 29, 2021 |
| FY2021 | Jul 31, 2020 | $50.0K | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | $0 | Nov 16, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | 0 | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 0 | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | 0 | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 0 | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | 0 | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | 0 | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | 0 | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | 0 | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | 0 | Nov 14, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | 0 | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 0 | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | 0 | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 0 | Oct 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 96.71M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | 96.71M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 79.07M | Nov 13, 2024 |
| FY2023 | Jul 31, 2022 | 77.86M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 87.19M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | 88.56M | Oct 29, 2021 |
| FY2021 | Jul 31, 2019 | 86.99M | Nov 16, 2020 |
| FY2019 | Jul 31, 2018 | 61.41M | Nov 13, 2020 |
| FY2018 | Jul 31, 2017 | 114.75M | Dec 12, 2018 |
| FY2017 | Jul 31, 2016 | 114.75M | Nov 14, 2017 |